14 Sydney healthtech investors backing digital health founders in 2026

14 healthtech investors are actively backing Sydney companies in 2026. Australia's digital health market hit USD $8.9B in 2025, forecast to reach $31.1B by 2034. Harrison.ai raised $112M Series C in February 2025. Eucalyptus sold to Hims & Hers at a $1.6B valuation in 2026.

Sydney is Australia's healthtech capital. Harrison.ai, Eucalyptus, and Heidi all operate out of NSW, and the investors who backed them are still deploying in 2026.

Healthtech VCs differ from generalist funds. They evaluate clinical evidence, regulatory pathways, and reimbursement models before assessing product-market fit. If you can't explain your TGA or FDA strategy, most won't engage.

Set up an Ellty data room before approaching any Sydney healthtech investor. Digital health due diligence includes clinical data, regulatory filings, and partnership agreements - a trackable data room shows VCs you're ready.

What is a Sydney healthtech investor?

Sydney healthtech investors back founders building digital health, AI diagnostics, telehealth, aged care tech, and medical devices. They differ from generalist VCs - they evaluate regulatory pathways and clinical evidence first.

Check sizes range from $500K seed checks from Investible to $30M+ growth equity from OneVentures. Most Sydney healthtech VCs want TGA-ready products or a clear FDA pathway before leading a Series A.

Australia's digital health market hit USD $8.9B in 2025 and is forecast to reach $31.1B by 2034. Private healthtech fundraising reached AUD $416M across 11 deals in 2025 - a 101% increase over 2024. That growth is pulling more capital toward NSW founders.

Compare how New South Wales investors approach the healthtech sector. NSW has both specialist healthtech VCs and generalist funds with explicit digital health mandates.

14 Sydney healthtech investors backing digital health founders

1. OneVentures

OneVentures is one of Australia's most established VC platforms, managing $900M+ across eight technology and healthcare funds. Founded by Michelle Deaker in 2006. Latest investments: Vaxxas Series D (August 2025) and me&u (April 2026). Portfolio standouts include BiVACOR - an artificial heart company. Phocas exited in October 2025. OneVentures writes $5M-$30M growth equity and venture debt checks.

Upload your clinical data, financial model, and IP strategy to Ellty before approaching OneVentures. They run structured diligence and expect full documentation ready before the second meeting.

• Recent Deals: Vaxxas Series D August 2025; me&u April 2026; Phocas exit October 2025; $900M+ AUM
• LinkedIn: OneVentures LinkedIn
• Sector Focus: Healthtech, life sciences, SaaS, healthcare AI, medtech
• Stage Focus: Series B to growth ($5M-$30M growth equity and venture debt)
• Location: Sydney, NSW, AU
• Website: one-ventures.com.au

2. Blackbird Ventures

Blackbird is Australia's most active VC with 356 investments since 2012 and $10B+ in portfolio value. They backed Eucalyptus from seed through its $1.6B acquisition by Hims & Hers in 2026. Latest investment in Kimia (April 2026). They backed Harrison.ai in its $112M Series C as an existing investor. Blackbird doesn't have a dedicated healthtech mandate but will back founders building category-defining health platforms.

Use Ellty when sending materials to Blackbird. Analytics showing which investors read your clinical validation data tells you where to follow up.

• Recent Deals: Eucalyptus $1.6B exit 2026; Kimia seed April 2026; Harrison.ai Series C existing investor; 11 investments past 12 months
• LinkedIn: Blackbird Ventures LinkedIn
• Sector Focus: Healthtech, AI, enterprise software, deep tech, consumer
• Stage Focus: Seed to growth ($500K-$50M+)
• Location: Sydney, NSW, AU
• Website: blackbird.vc

3. AirTree Ventures

AirTree closed a $650M Fund V in August 2025. They backed Eucalyptus from early stage through its $1.6B Hims & Hers acquisition in 2026. They also invested in Human Health - an AI-powered chronic illness platform by former Canva executives - in 2025. With $250M seed and $400M growth vehicles, AirTree can write healthtech checks at any stage.

Set up an Ellty data room before approaching AirTree. They run structured processes and will request clinical validation, retention data, and financial projections in the first diligence round.

• Recent Deals: Eucalyptus $1.6B exit 2026; Human Health seed 2025; Ambience Healthcare pre-seed 2025; $650M Fund V August 2025
• LinkedIn: AirTree LinkedIn
• Sector Focus: Healthtech, AI, digital health, consumer health, digital therapeutics
• Stage Focus: Seed through growth ($500K-$20M+)
• Location: Sydney, NSW, AU
• Website: airtree.vc

4. Artesian

Artesian manages $1.22B+ in assets with 600+ startup investments. They run the Actuator Medtech VC Fund for medtech and digital health. Artesian is one of the top 2 investors in Australian healthtech by deal count. In February 2026, HBF partnered with Artesian on a new A$25M healthtech fund. Recent exits include Neighbourlytics (acquired by REA Group, November 2025). 2026 investments include CLIQ and Plasmaleap.

Read the due diligence process guide before engaging Artesian. They use a formal investment committee process and expect regulatory documentation ready.

• Recent Deals: HBF Ventures A$25M fund partnership February 2026; Neighbourlytics exit November 2025; CLIQ and Plasmaleap 2026
• LinkedIn: Artesian LinkedIn
• Sector Focus: Medtech, healthtech, agrifood, clean energy
• Stage Focus: Seed to Series A ($1M-$10M)
• Location: Sydney, NSW, AU
• Website: artesianinvest.com

5. Skip Capital

Skip Capital is the family office of Atlassian co-founder Scott Farquhar and Kim Jackson, based in Sydney. They backed Human Health's $8.5M seed round in 2025 alongside AirTree and LocalGlobe. Portfolio includes Alloy, Morse Micro, and Pyn. Skip Capital invests across healthtech, wellness, AI, and infrastructure. They're patient, high-conviction investors who rarely lead but add serious credibility.

• Recent Deals: Human Health seed $8.5M 2025; Lorikeet Series A August 2025; Alloy, Morse Micro, Pyn portfolio
• LinkedIn: Skip Capital LinkedIn
• Sector Focus: Healthtech, wellness, AI, technology, education, robotics
• Stage Focus: Seed to Series B
• Location: Sydney, NSW, AU
• Website: skipcapital.com

6. Dreamoro Ventures

Dreamoro Group is Australia's only specialist healthtech VC and digital health studio, based in Sydney. Founded in 2022 with an $80M Fund I target. They invest pre-seed to Series A in prevention, AI-enabled health, and digital therapeutics. Their studio model means they co-build companies alongside founders, not just write checks. For founders tackling chronic disease, mental health, or preventive care, Dreamoro is the right first conversation.

• Recent Deals: Fund I actively deploying; specialist digital health focus; studio and VC hybrid model
• LinkedIn: Dreamoro LinkedIn
• Sector Focus: Digital health, AI-enabled health, prevention, digital therapeutics
• Stage Focus: Pre-seed to Series A
• Location: Sydney, NSW, AU
• Website: dreamoro.com.au

7. Main Sequence

Main Sequence is CSIRO's $1B+ deep tech VC managing three funds. Fund 3 commenced in 2023 with 16 investments made so far. They back health, food, space, security, and decarbonisation. Main Sequence backed Kasada's $20M round (December 2025). For healthtech founders from UNSW, University of Sydney, or CSIRO research backgrounds, Main Sequence is the most relevant first institutional investor.

• Recent Deals: Kasada $20M December 2025; 10 investments past 12 months; A$1B+ AUM; Fund 4 raise expected late 2026
• LinkedIn: Main Sequence LinkedIn
• Sector Focus: Health, food, space, transport, security, decarbonisation
• Stage Focus: Seed to Series B ($1M-$20M)
• Location: Sydney, NSW, AU
• Website: mseq.vc

8. Investible

Investible is a Sydney early-stage VC with 197 investments and 15 exits including 2 IPOs. They back digital health alongside climate tech and deep tech. 12 investments in the past 12 months. For healthtech founders raising sub-$3M rounds, Investible's combination of a formal VC fund and the Club Investible global community gives both capital and warm follow-on introductions.

• Recent Deals: 12 investments past 12 months; 197 total investments; 15 exits; active 2025-2026
• LinkedIn: Investible LinkedIn
• Sector Focus: Healthtech, climate tech, deep tech, software, AI
• Stage Focus: Seed to Series A ($250K-$3M)
• Location: Sydney, NSW, AU
• Website: investible.com

9. Square Peg Capital

Square Peg is a global VC with Sydney HQ managing $3.6B+ USD with 194 investments. They participated in Harrison.ai's $112M Series C in February 2025. Square Peg invests across healthtech, AI, fintech, and SaaS from seed to Series B. Their global network in Israel, Southeast Asia, and the US adds international distribution value for health AI companies.

Use Ellty to prepare a data room before Square Peg engagement. They run disciplined diligence and expect full financial projections, clinical KPIs, and regulatory status docs.

• Recent Deals: Harrison.ai Series C investor 2025; Aidoc April 2026; 194 total investments; $3.6B+ USD AUM
• LinkedIn: Square Peg LinkedIn
• Sector Focus: Healthtech, AI, fintech, SaaS, enterprise software
• Stage Focus: Seed to Series B ($2M-$20M)
• Location: Sydney, NSW, AU (global)
• Website: squarepeg.vc

10. Brandon Capital

Brandon Capital is Australia's leading life sciences VC, founded in 2007 with 45 investments and 2 new investments in the past 12 months. They focus on medtech and life sciences startups with strong IP and clinical traction. Brandon Capital co-invests frequently with Uniseed. Recent portfolio includes Lumonus ($28M Series B top-up, March 2026) and ENA Respiratory ($34M, October 2025).

Read the IP due diligence guide before approaching Brandon Capital. Life sciences VCs prioritise IP defensibility above product metrics.

• Recent Deals: Lumonus $28M Series B top-up March 2026; ENA Respiratory $34M October 2025; 45 total investments
• LinkedIn: Brandon Capital LinkedIn
• Sector Focus: Life sciences, medtech, healthtech, drug development
• Stage Focus: Seed to Series B ($2M-$20M+)
• Location: Melbourne/Sydney, AU
• Website: brandoncapital.vc

11. HBF Ventures

HBF Ventures is the VC arm of HBF, Australia's second-largest member-based health fund with 1M+ members. Launched February 9, 2026 with a A$25M fund managed via Artesian's VCaaS platform. They target health tech startups from seed to Series A and bring direct health insurer network access as a strategic LP. Right for founders building prevention, diagnostics, or care management tools.

• Recent Deals: Fund launched February 2026; A$25M initial fund; Artesian-managed; health insurer strategic LP
• LinkedIn: HBF LinkedIn
• Sector Focus: Health tech, digital health, prevention, diagnostics, care management
• Stage Focus: Seed to Series A
• Location: Perth/Sydney, AU
• Website: hbf.com.au

12. Uniseed

Uniseed is Australia's university-backed commercialisation fund, supporting research from UNSW, University of Sydney, University of Queensland, and CSIRO. Fund 3 launched in 2015. They co-invest frequently with Brandon Capital across life sciences and medtech. Uniseed is the right first investor if your healthtech originated from research at one of its partner universities.

• Recent Deals: Active Fund 3 deploying; partner universities include UNSW and University of Sydney; Brandon Capital co-investor
• LinkedIn: Uniseed LinkedIn
• Sector Focus: Life sciences, medtech, health AI, university spinouts
• Stage Focus: Pre-seed to seed ($500K-$3M)
• Location: Sydney, NSW, AU
• Website: uniseed.com

13. Aware Super

Aware Super is one of Australia's largest superannuation funds and co-led Harrison.ai's $112M Series C in February 2025 alongside ECP and Horizons Ventures. Superannuation funds are increasingly writing direct growth checks into healthtech. Aware Super is the right target for founders raising $10M+ in AI diagnostics, digital health infrastructure, or aged care tech.

• Recent Deals: Harrison.ai $112M Series C co-lead February 2025; direct growth-stage healthtech investment
• LinkedIn: Aware Super LinkedIn
• Sector Focus: Healthtech, AI diagnostics, digital health infrastructure, aged care
• Stage Focus: Growth rounds ($10M-$100M+)
• Location: Sydney, NSW, AU
• Website: aware.com.au

14. TEN13

TEN13 is an angel syndicate VC with 70+ investments and strong NSW deal flow. They back founders at seed in healthtech, SaaS, AI, and deep tech with $250K-$2M per syndicate round. For healthtech founders raising their first $500K-$1.5M who aren't ready for institutional VCs, TEN13's syndicate model closes faster than a traditional fund process.

• Recent Deals: 70+ investments; active 2025-2026 deployments; angel syndicate model with national reach
• LinkedIn: TEN13 LinkedIn
• Sector Focus: Healthtech, SaaS, AI, deep tech, ANZ founders
• Stage Focus: Seed ($250K-$2M per syndicate)
• Location: Brisbane/Sydney, AU
• Website: ten13.vc

How healthtech due diligence differs from standard VC

Sydney healthtech VCs run a two-track diligence process. Track one is regulatory - TGA status, FDA pathway, clinical evidence, and reimbursement strategy. Track two is the standard commercial track - financials, unit economics, team, and market size.

Most NSW healthtech VCs won't progress to commercial diligence until the regulatory track clears. Don't wait until you're in a funding process to organise your clinical data and compliance documentation.

Use Ellty to build a data room with separate sections for regulatory, clinical, and commercial materials. OneVentures, Artesian, and Brandon Capital all request this structure within the first diligence exchange.

Where to find warm intros to Sydney healthtech investors

Key events are AusBiotech Health Futures, the Digital Health Summit, and Stone & Chalk's NSW health program. Most Sydney healthtech VCs attend at least two per year.

Victoria investors frequently co-invest with Sydney healthtech funds. Brandon Capital, Artesian, and Uniseed all maintain active co-investment relationships with Melbourne-based counterparts.

Research Commonwealth and State Government grants before your first VC meeting. Founders who've secured MRFF, Biomedical Translation Fund, or NSW Health grants de-risk regulatory spend. Investors notice.

What Sydney healthtech VCs look for in 2026

AI diagnostics and remote monitoring accounted for 58% of healthtech capital raised in early 2026. If you're building in these categories, lead with clinical evidence of diagnostic accuracy - not product features.

Most Sydney healthtech investors are tired of broad digital health claims without unit economics. Harrison.ai hit $112M Series C by showing 50% penetration of Australian radiologists and 12 FDA clearances. That's the 2026 benchmark.